Wall Street further embraced Abbott Laboratories as it beat expectations and raised its 2019 guidance. Investors doubled down on the prospects for the med-tech company to outperform its large cap peers, pushing shares (NYSE:ABT) up by 5% in the wake of its June 17 earnings announcement.